-
1 Comment
Zhejiang Hisun Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 7.5% below its 200 day moving average.
From a valuation standpoint, the stock is 86.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Zhejiang Hisun Pharmaceutical Co., Ltd's total revenue rose by 16.0% to $3B since the same quarter in the previous year.
Its net income has increased by 106.4% to $75M since the same quarter in the previous year.
Finally, its free cash flow grew by 6692.1% to $214M since the same quarter in the previous year.
Based on the above factors, Zhejiang Hisun Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE0000013Z2 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 11B |
|---|---|
| Beta | 0.59 |
| Target Price | 6.3 |
| PE Ratio | 18.65 |
| Dividend Yield | None |
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss, anti-viral, anti-TB, animal healthcare, and others. The company also exports its products to approximately 70 countries worldwide. The company was founded in 1956 and is headquartered in Taizhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600267.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
